Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 912345...Last »

Bexion Pharmaceuticals Early-Stage Cancer Drug Being Hailed as Game Changer

Bexion Pharmaceuticals and the drugmaker’s investigational cancer treatment BXQ-350 is receiving lots of mainstream media coverage as a potential game changer.

Read More »

Cashing in on DNA: race on to unlock value in genetic data

As millions of people pay for home tests to check on ancestry or health risks, genetic data is becoming an increasingly valuable resource for drugmakers, triggering a race to create a DNA marketplace.

Read More »

New SCOUT Poll Finds Americans Much Less Concerned About Security of Personal Health Information than Threats to Financial Information

Americans may have a false sense of security about the privacy and safety of their personal medical information.

Read More »

Verily, ResMed Team Up On Sleep Apnea Joint Venture

Google’s Verily will team up with ResMed, a company that specializes in treating sleep disorders, to launch a joint business venture to address sleep apnea and other sleeping disorders.

Read More »

Hitting cancer early: AstraZeneca’s bid to outmaneuver rivals

AstraZeneca suffered the company’s biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. Yet now two-thirds of analysts tracked by Thomson Reuters recommend the stock, making it one of the sector’s biggest consensus buys, and CEO Pascal Soriot says he is “absolutely” happy to carry on into the 2020s as he chases early use of modern cancer drugs.

Read More »

BBK Worldwide Repositions as The Patient Experience Company and Unveils New Brand Platform

BBK Worldwide – for 35 years on the crest of the wave with regard to the development and evolution of the patient recruitment industry – announced its new marketplace position as The Patient Experience Company.

Read More »

Study preserves hopes for Roche’s Tecentriq in lung cancer

A clinical trial showed positive survival data for Swiss drugmaker Roche’s potential immunotherapy cocktail as an initial treatment for an aggressive form of lung cancer.

Read More »

Novartis Receives FDA Approval For New Prescribing Information For Blockbuster PsA Treatment Cosentyx

FDA approved inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).

Read More »

Roche pays $2.4 billion for rest of cancer expert Foundation Medicine

Roche is paying $2.4 billion to buy the rest of Foundation Medicine, raising the Swiss drugmaker’s bet on the U.S. genomic profiling group’s ability to personalize cancer care.

Read More »

Selecta Unveils Expanded Positive Clinical Data for Gout Treatment

Watertown, Mass.-based Selecta Biosciences is eying a Phase III trial for its gout treatment based on expanded positive data from an ongoing mid-stage study that showed a significant reduction of serum uric acid at 12 weeks.

Read More »

Consumer perceptions of pharma: Behind the numbers

Innoplexus CEO Gunjan Bhardwaj responded to questions from Med Ad News about his company’s study of consumer perceptions of the pharma industry.

Read More »

Modern Marketing: Reaching analog humans in a digital world

The irony of marketing in 2018 is that while our opportunities to engage with customers continuously expand through a myriad of new, increasingly digital, channels, human brains remain stubbornly analog.

Read More »

Madrigal Pharma reports liver drug study success

Madrigal Pharmaceuticals’ shares more than doubled after mid-stage trial data showed the company’s lead drug reduced liver fat in patients with fatty liver disease.

Read More »

China overtakes U.S. for healthy lifespan: WHO data

China has overtaken the United States in healthy life expectancy at birth for the first time, according to World Health Organization data.

Read More »

Novartis’ digital drive continues with eye-disease app

Novartis’ foray into digital technology intensified as the Swiss drugmaker launched a mobile-phone based app to help collect data from people participating in eye disease studies.

Read More »

Roche and Subsidiaries Ramp Up Treatment Options for Multiple Sclerosis

Roche and its subsidiaries are ramping up treatment options for multiple sclerosis. In April, the company acquired a regenerative therapy program for MS from Inception Sciences. Now, Roche’s Genentech announced new data showcasing the efficacy of Ocrevus in relapsing multiple sclerosis (RMS).

Read More »

Akorn sues Fresenius over deal termination

U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.

Read More »

FDA staff raises safety concerns over arthritis drug

U.S. FDA staff flagged concerns about potentially fatal blood clots from higher doses of a rheumatoid arthritis drug developed by Eli Lilly and Co. and Incyte Corp.

Read More »

Alkermes Gains NDA Acceptance For MDD Treatment That Was Previously Rejected By The FDA

The U.S. FDA accepted Alkermes’ New Drug Application (NDA) for ALKS 5461, a treatment for major depressive disorder

Read More »

How Blockchain Might be Used by Biopharma to Trade Data

Blockchain is best known as being linked to the cryptocurrency Bitcoin. For those a bit more in the know, it is the underlying data infrastructure that allows Bitcoin to work.

Read More »

Page 1 of 912345...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2018 Focus: Biotech, Payer Access, DTC and more!


Ad Right Bottom

Main Navigation